Literature DB >> 34158260

Prevalence and impact of antimicrobial resistance in gastrointestinal infections: A review.

R Contreras-Omaña1, A E Escorcia-Saucedo2, J A Velarde-Ruiz Velasco3.   

Abstract

Antimicrobial resistance has become a worldwide problem due to its excessive increase in recent years. The aim of the present review was to bring together data from different articles describing the levels of antimicrobial resistance in the most common gastrointestinal infections reported across the globe. The literature search was carried out in Google Scholar, Medline, Embase, and Pubmed, with the terms "antimicrobial resistance", "resistance in gastrointestinal disorders", and "resistance in amoebiasis", in Spanish and English. Mexican treatment guidelines and consensuses from 2017 to the present were utilized. Publications from the last ten years were chosen to describe the level of resistance. They had adequate sample sizes, the Material and Methods sections were precise, and they included multicenter studies, national and international consensuses, meta-analyses, systematic reviews, and extensive texts. The final number of articles was 51. The microorganisms that demonstrated the highest percentage of resistance were Helicobacter pylori (metronidazole 50%-80%, clarithromycin 20%-40%, and levofloxacin 30%-35%), Clostridioides difficile (clindamycin 8.3%-100%, cephalosporines 51%), Campylobacter jejuni and Campylobacter coli (fluoroquinolones 85%), Escherichia coli (ampicillin 76.5%), Entamoeba histolytica (metronidazole 50%), and bacterial peritonitis (third-generation cephalosporines 40%, methicillin 85%). Antimicrobial resistance is reaching elevated percentages, making it necessary to evaluate the situation of each patient, to successfully treat gastrointestinal infections.
Copyright © 2021 Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. All rights reserved.

Entities:  

Keywords:  Antimicrobial resistance; Gastrointestinal infections; Infecciones gastrointestinales; Resistencia antimicrobiana; Tratamiento; Treatment

Year:  2021        PMID: 34158260     DOI: 10.1016/j.rgmxen.2021.06.004

Source DB:  PubMed          Journal:  Rev Gastroenterol Mex (Engl Ed)        ISSN: 2255-534X


  2 in total

1.  In Silico Screening and In Vitro Assessment of Natural Products with Anti-Virulence Activity against Helicobacter pylori.

Authors:  Maciej Spiegel; Paweł Krzyżek; Ewa Dworniczek; Ryszard Adamski; Zbigniew Sroka
Journal:  Molecules       Date:  2021-12-21       Impact factor: 4.411

Review 2.  When to Use Antibiotics in COVID-19: A Proposal Based on Questions.

Authors:  Carmelo Dueñas-Castell; Camilo Jose Polanco-Guerra; Maria Cristina Martinez-Ávila; Amilkar J Almanza Hurtado; Tómas Rodriguez Yanez; Juan Camilo Gutierrez-Ariza; Jorge Rico-Fontalvo
Journal:  Cureus       Date:  2022-07-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.